Literature DB >> 1566745

Hereditary factor VII deficiency in pregnancy: peripartum treatment with factor VII concentrate.

L E Robertson1, N Wasserstrum, E Banez, M Vasquez, D A Sears.   

Abstract

This report describes pregnant sisters with severe factor VII deficiency and peripartum management with factor VII concentrate. In this family, two affected members had previously developed severe postpartum hemorrhage when managed with fresh frozen plasma. Therapy-related complications owing to plasma infusion included viral disease transmission and pulmonary edema. Therefore, to lessen the risks of complications, specific factor therapy was initiated shortly before parturition in both patients. Factor VII concentrate was administered prior to delivery and every 6 hr for the next 72 hr to keep trough levels at approximately 10%. Based on peak and trough levels, the mean factor VII half-lives were determined to be 3.6 and 5.7 hr. Use of the concentrate was associated with uncomplicated delivery and minimal postpartum bleeding.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1566745     DOI: 10.1002/ajh.2830400108

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  3 in total

1.  Successful excision of hemorrhagic cavernous angioma in a patient with severe factor VII deficiency: perioperative treatment with factor VII concentrate.

Authors:  A Brunori; R Greco; G Oddi; A de Blasio; F Chiappetta
Journal:  Neurosurg Rev       Date:  1997       Impact factor: 3.042

2.  Tissue factor is required for uterine hemostasis and maintenance of the placental labyrinth during gestation.

Authors:  J Erlich; G C Parry; C Fearns; M Muller; P Carmeliet; T Luther; N Mackman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

Review 3.  Is prophylaxis required for delivery in women with factor VII deficiency?

Authors:  L M Baumann Kreuziger; Colleen T Morton; Mark T Reding
Journal:  Haemophilia       Date:  2013-04-22       Impact factor: 4.287

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.